Many new gene therapy treatments aren’t as profitable as predicted. But the reasons why don’t quite fit Goldman Sachs’ ...

Reports of insurance companies delaying approval of medical treatments, or outright denying them, for American patients, ...

Shares of several pharmaceutical companies were up after President Trump signed an executive order aimed at accelerating research, development access to psychedelic medicines for the treatment of ...

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal ...

Angelica Vazquez claims she was "treated with hostility and exclusion" while working as a housekeeper at Jenner's Hidden ...

Riverkeeper and SELC say 3 Sumter industries are releasing PFAS “forever chemicals” into the Sumter-Pocotaligo River, and ...

AnaptysBio has spun off its biopharma pipeline into First Tracks Biotherapeutics, shifting to a royalty-focused, virtual ...

Competitive attrition and market consolidation were referenced, with Palmer stating, "perhaps that is an indication that the ...

Range reports that with upcoming IPOs, employees must plan equity strategies to avoid hefty tax bills and financial pitfalls ...

The only drug named in Trump’s executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD ...

Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, ...

Today, Senator Jim Banks (R-Ind.) sent a letter to the Federal Trade Commission Chairman, Andrew Ferguson, urging the ...